Medication info
Irbesartan Plus 300/12.5 mg Tablet

Irbesartan Plus 300/12.5 mg Tablet

Prescription medicationTabletOral
Ingredient · strength
Irbesartan›300mg / 1 tabletHydrochlorothiazide›12.5mg / 1 tablet
Manufacturer / importer
Hanmi Pharmaceutical Co., Ltd.
Appearance
Pink rectangular film-coated tablets
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 200809588 · Notified 2008.09.17 · Insurance code 643504400

Summary

Main use
Treatment of essential hypertension
Who takes it
Adults · Children
Adult dose
This medicine is administered once daily, regardless of meals. Dose titration for each component (irbesartan and hydrochlorothiazide) is recommended. ○ Adults 1. Patients whose blood pressure is not adequately controlled with monotherapy - Administer 1 tablet of irbesartan 150 mg/hydrochlorothiazide 12.5 mg once daily to patients whose blood pressure is not adequately controlled with irbesartan 150 mg or hydrochlorothiazide alone. - Administer 1 tablet of irbesartan 300 mg/hydrochlorothiazide 12.5 mg once daily to patients whose blood pressure is not adequately controlled with irbesartan 300 mg or irbesartan 150 mg/hydrochlorothiazide 12.5 mg. - Administer 1 tablet of irbesartan 300 mg/hydrochlorothiazide 25 mg once daily to patients whose blood pressure is not adequately controlled with irbesartan 300 mg/hydrochlorothiazide 12.5 mg. Doses exceeding irbesartan 300 mg/hydrochlorothiazide 25 mg are not recommended. If necessary, this medicine may be co-administered with other antihypertensive agents. 2. If this medicine is to be administered as initial therapy to patients with moderate or severe hypertension (stage 2), individualize treatment by considering baseline blood pressure, target blood pressure, and the anticipated increase in the likelihood of achieving the treatment target compared with monotherapy. Usually, start with 1 tablet of irbesartan 150 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure control is needed, the dose may be increased after 1 ~ 2 weeks to a maximum of irbesartan 300 mg/hydrochlorothiazide 25 mg. Use of this medicine as initial therapy is not recommended in patients with intravascular volume depletion. ○ Patients with renal impairment Because of the hydrochlorothiazide component, this medicine is not recommended for patients with severe renal impairment (creatinine clearance〈 30 mL/min). Loop diuretics are preferred in this patient population. No dose adjustment is necessary in patients with renal impairment and creatinine clearance of 30 mL/min or higher. ○ Patients with volume depletion If sodium and/or fluid depletion is present, correct the imbalance before administering this medicine. ○ Patients with hepatic impairment This medicine is not to be used in patients with severe hepatic impairment. Thiazide drugs should be used with caution in patients with hepatic impairment. No dose adjustment is necessary in patients with mild ~ moderate hepatic impairment. ○ Older adults No dose adjustment is necessary in older adults.
Child dose
○ Children The safety and efficacy of this medicine have not been established in children and adolescents under 18 years of age.

Ingredients

Manufacturer
Hanmi Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension

  • Essential hypertension
  • moderate hypertension
  • severe hypertension
View approved original text

This medication is used for patients with essential hypertension. It is effective even when blood pressure is not adequately controlled by monotherapy, particularly for moderate to severe hypertensive patients who are starting treatment with a combination therapy to reach target blood pressure. Thus, it helps effectively manage blood pressure across various stages of hypertension.

How to take

Adult dose

This medicine is administered once daily, regardless of meals. Dose titration for each component (irbesartan and hydrochlorothiazide) is recommended. ○ Adults 1. Patients whose blood pressure is not adequately controlled with monotherapy - Administer 1 tablet of irbesartan 150 mg/hydrochlorothiazide 12.5 mg once daily to patients whose blood pressure is not adequately controlled with irbesartan 150 mg or hydrochlorothiazide alone. - Administer 1 tablet of irbesartan 300 mg/hydrochlorothiazide 12.5 mg once daily to patients whose blood pressure is not adequately controlled with irbesartan 300 mg or irbesartan 150 mg/hydrochlorothiazide 12.5 mg. - Administer 1 tablet of irbesartan 300 mg/hydrochlorothiazide 25 mg once daily to patients whose blood pressure is not adequately controlled with irbesartan 300 mg/hydrochlorothiazide 12.5 mg. Doses exceeding irbesartan 300 mg/hydrochlorothiazide 25 mg are not recommended. If necessary, this medicine may be co-administered with other antihypertensive agents. 2. If this medicine is to be administered as initial therapy to patients with moderate or severe hypertension (stage 2), individualize treatment by considering baseline blood pressure, target blood pressure, and the anticipated increase in the likelihood of achieving the treatment target compared with monotherapy. Usually, start with 1 tablet of irbesartan 150 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure control is needed, the dose may be increased after 1 ~ 2 weeks to a maximum of irbesartan 300 mg/hydrochlorothiazide 25 mg. Use of this medicine as initial therapy is not recommended in patients with intravascular volume depletion. ○ Patients with renal impairment Because of the hydrochlorothiazide component, this medicine is not recommended for patients with severe renal impairment (creatinine clearance〈 30 mL/min). Loop diuretics are preferred in this patient population. No dose adjustment is necessary in patients with renal impairment and creatinine clearance of 30 mL/min or higher. ○ Patients with volume depletion If sodium and/or fluid depletion is present, correct the imbalance before administering this medicine. ○ Patients with hepatic impairment This medicine is not to be used in patients with severe hepatic impairment. Thiazide drugs should be used with caution in patients with hepatic impairment. No dose adjustment is necessary in patients with mild ~ moderate hepatic impairment. ○ Older adults No dose adjustment is necessary in older adults.

Child dose

○ Children The safety and efficacy of this medicine have not been established in children and adolescents under 18 years of age.

Precautions

This medication can cause serious harm to the fetus and newborn during pregnancy, so it must be discontinued immediately if pregnancy is confirmed. Pregnant women and nursing mothers should not take this medication. Patients with severely impaired kidney function, anuria, specific electrolyte abnormalities, or liver dysfunction should also refrain from using this drug. This medication should be administered cautiously to patients with hypotension, kidney function abnormalities, liver dysfunction, or heart issues, as the risk of skin cancer may increase, and regular monitoring of skin conditions is necessary. During treatment, side effects such as dizziness, fatigue, nausea, vomiting, and urination abnormalities may occur, and if symptoms are severe, consultation with a physician is necessary. Dizziness or fatigue may occur while driving or operating machinery, so caution is needed. Blood pressure may drop too low or electrolyte imbalances may occur; hence, especially in cases of diarrhea, vomiting, or excessive use of diuretics, it is crucial to ensure adequate sodium and fluid intake as directed by a physician. Diabetic patients may be affected in blood sugar control, so it is important to manage blood glucose and medication dosage well both before and during treatment. This medication may interact with other drugs, especially with lithium, drugs affecting potassium, heart medications, and anti-inflammatory agents, so consultation with a physician or pharmacist is essential when used in conjunction with them. In cases of overdose, symptoms may include hypotension, electrolyte imbalances, and dehydration; immediate medical attention is required. It is not recommended for children or adolescents as safety and efficacy have not been established, and caution is warranted with the elderly as they may be more sensitive to this medication. Keep the medication out of reach of children, and store it securely in its original container.

Side effects

  • Dizziness
  • fatigue
  • nausea
  • vomiting
  • abnormal urination
  • elevated BUN
  • elevated creatine kinase
  • elevated creatinine
  • orthostatic dizziness
  • headache
Show 81 more
  • fainting
  • low blood pressure
  • tachycardia
  • edema
  • flushing
  • cough
  • diarrhea
  • dyspepsia
  • altered taste
  • jaundice
  • hepatitis
  • abnormal liver function
  • sexual dysfunction
  • changes in libido
  • renal function impairment
  • limb edema
  • arthralgia
  • myalgia
  • tinnitus
  • vascular edema
  • rash
  • urticaria
  • hyperkalemia
  • decreased serum potassium
  • decreased serum sodium
  • low blood pressure
  • shingles
  • colon cancer
  • hematoma
  • anaphylactic shock
  • anaphylactic reaction
  • intestinal vascular edema
  • anemia
  • thrombocytopenia
  • hypoglycemia
  • depression
  • sleep disorders
  • orthostatic hypotension
  • arrhythmia
  • aplastic anemia
  • bone marrow suppression
  • neutropenia
  • agranulocytosis
  • hemolytic anemia
  • leukopenia
  • thrombocytopenia
  • dyspnea
  • pancreatitis
  • loss of appetite
  • constipation
  • gastric irritation
  • sialadenitis
  • loss of appetite
  • interstitial nephritis
  • renal impairment
  • temporary blurred vision
  • yellow vision
  • weakness
  • muscle twitching
  • toxic epidermal necrolysis
  • necrotizing vasculitis
  • erythema multiforme-like reaction
  • photosensitivity
  • fever
  • electrolyte imbalance
  • hyperuricemia
  • diabetes
  • hyperglycemia
  • elevated cholesterol and triglycerides
  • hypokalemia
  • hyponatremia
  • hypochloremic alkalosis
  • muscle cramps
  • somnolence
  • restlessness
  • myalgia
  • convulsions
  • muscle fatigue
  • increased urination
  • headache
  • dizziness

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, so it must be stored in a tightly sealed container. The storage temperature should maintain room temperature between 1 to 30 degrees Celsius. This ensures the medication remains effective and safe for an extended period.

Appearance and packaging

Appearance

Pink rectangular film-coated tablets

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.